



ASX Release

4 September 2025

Received \$3.04 million R&D Tax Incentive Rebate for FY25

Melbourne, Australia; Acrux Limited (ASX:ACR) is pleased to announce it has received its FY25 R&D Tax Incentive rebate ('RDTI') from the Australian Tax Office totalling \$3,040,367 and the associated short term funding facility provided by Radium Capital has been repaid in full.

The RDTI is an Australian Federal Government program under which companies may receive cash rebates for eligible research and development expenditure. It reflects Acrux's ongoing commitment to investing in Australian research and development that will generate future commercial income. It also reflects the Australian government's commitment to building a smarter future based on Australian science.

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

John Warmbrunn

Acrux Limited

CEO & Managing Director

P: + 61 3 8379 0100

E: john.warmbrunn@acrux.com.au

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

For further information on Acrux, visit www.acrux.com.au